LANSING, Mich., Dec. 18, 2014 — Neogen Corporation (NASDAQ: NEOG) announced today that its net income for the second quarter of fiscal 2015, which ended Nov. 30, increased 26% to $7,806,000, when compared to the prior year’s $6,207,000. Earnings per share in the current quarter were $0.21, compared to $0.17 a year ago. Current year-to-date net income was $16,689,000, or $0.45 per share, compared to $14,045,000, or $0.38 per share, for the same period a year ago.
Revenues for the second quarter of fiscal 2015 increased 15% to $68,455,000, from the previous year’s second quarter revenues of $59,599,000. This increase was aided in part by recent acquisitions completed by the company. The quarterly revenue and net income results represent second quarter records for the 32-year-old company. Year to date, FY 2015 revenues increased 15% to $136,054,000 from FY 2014′s $118,147,000. [ More ... ]
Across Europe there is an increasing trend in the prevalence of substance abuse among the working population. Statistics show that these figures spike in December as people enter the festive spirit where we see as much as a 40% increase in the consumption of drugs and alcohol. [ More ... ]
Used to evaluate or discover kidney disease, kidney failure or malfunction, a creatinine test is a relatively common test that medical professionals often order when treating patients with conditions that affect the kidneys such as high blood pressure, type-one or type-two diabetes, or in those that are taking medication that can affect kidney function.
Because creatinine is a chemical waste product that’s produced by muscle metabolism, The Mayo Clinic states that healthy kidneys are able to filter creatinine and other waste products from blood. However, when kidneys are not working properly, higher than normal levels of creatinine become apparent in blood and urine and alert medical professionals of a potential problem. [ More ... ]